Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Bought by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC lifted its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 79.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,498 shares of the biotechnology company’s stock after acquiring an additional 6,424 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Arrowhead Pharmaceuticals were worth $281,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Fifth Third Bancorp boosted its holdings in shares of Arrowhead Pharmaceuticals by 42.5% during the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 354 shares during the last quarter. Values First Advisors Inc. acquired a new stake in Arrowhead Pharmaceuticals in the 3rd quarter worth about $52,000. Headlands Technologies LLC grew its holdings in Arrowhead Pharmaceuticals by 7,696.8% in the 1st quarter. Headlands Technologies LLC now owns 2,417 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 2,386 shares during the period. Meeder Asset Management Inc. lifted its holdings in shares of Arrowhead Pharmaceuticals by 4,629.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 3,333 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Arrowhead Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 788 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research note on Thursday, October 17th. B. Riley reiterated a “buy” rating and issued a $55.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, August 12th. Royal Bank of Canada restated an “outperform” rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Friday, October 11th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.33.

Arrowhead Pharmaceuticals Price Performance

NASDAQ ARWR opened at $21.89 on Monday. The company’s fifty day simple moving average is $20.33 and its 200-day simple moving average is $23.48. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $17.05 and a 52 week high of $39.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.80). During the same period in the previous year, the business posted ($0.96) EPS. The company’s quarterly revenue was down 100.0% compared to the same quarter last year. On average, equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -4.31 earnings per share for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.